Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer

被引:0
作者
Shen, Qiang [1 ]
Murakami, Kiichi [1 ]
Sotov, Valentin [1 ]
Butler, Marcus [1 ,2 ,3 ]
Ohashi, Pamela S. [1 ,4 ,5 ]
Reedijk, Michael [1 ,5 ,6 ]
机构
[1] Univ Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada
[4] Univ Toronto, Dept Immunol, Med Sci Bldg,1 Kings Coll Circle,Room 7205, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, MaRS Ctr, Dept Med Biophys, Toronto Med Discovery Tower,101 Coll St,Room 15-70, Toronto, ON M5G 2M9, Canada
[6] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 8-411, Toronto, ON M5G 2M9, Canada
基金
加拿大健康研究院;
关键词
TUMOR-ASSOCIATED MACROPHAGES; SIGNALING PATHWAY; CELLS; INFLAMMATION; NIVOLUMAB; THERAPY; INVASIVENESS; EXPRESSION; MICROENVIRONMENT; PEMBROLIZUMAB;
D O I
10.1126/sciadv.ado8275
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aberrant Notch, which is a defining feature of triple-negative breast cancer (TNBC) cells, regulates intercellular communication in the tumor immune microenvironment (TIME). This includes tumor-associated macrophage (TAM) recruitment through Notch-dependent cytokine secretion, contributing to an immunosuppressive TIME. Despite the low response rate of TNBC to immune checkpoint blockade (ICB), here, we report that inhibition of Notch-driven cytokine-mediated programs reduces TAMs and induces responsiveness to sequentially delivered ICB. This is characterized by the emergence of GrB+ cytotoxic T lymphocytes (CTLs) in the primary tumor. A more impressive effect of sequential treatment is observed in the lung where TAM depletion and increased CTLs are accompanied by near-complete abolition of metastases. This is due to (i) therapeutic reduction in Notch-dependent, prometastatic circulating factors released by the primary tumor, and (ii) elevated PD ligand 1 (PD-L1) in lung metastases, rendering them profoundly sensitive to ICB. These findings highlight the potential of combination cytokine inhibition and ICB as an immunotherapeutic strategy in TNBC.
引用
收藏
页数:14
相关论文
共 50 条
[1]   Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer [J].
Isaacs, James ;
Anders, Carey ;
McArthur, Heather ;
Force, Jeremy .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (05)
[2]   Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer [J].
Michel, Laura L. ;
von Au, Alexandra ;
Mavratzas, Athanasios ;
Smetanay, Katharina ;
Schuetz, Florian ;
Schneeweiss, Andreas .
TARGETED ONCOLOGY, 2020, 15 (04) :415-428
[3]   Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer [J].
James Isaacs ;
Carey Anders ;
Heather McArthur ;
Jeremy Force .
Current Treatment Options in Oncology, 2021, 22
[4]   Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer [J].
Sceneay, Jaclyn ;
Goreczny, Gregory J. ;
Wilson, Kristin ;
Morrow, Sara ;
DeCristo, Molly J. ;
Ubellacker, Jessalyn M. ;
Qin, Yuanbo ;
Laszewski, Tyler ;
Stover, Daniel G. ;
Barrera, Victor ;
Hutchinson, John N. ;
Freedman, Rachel A. ;
Mittendorf, Elizabeth A. ;
McAllister, Sandra S. .
CANCER DISCOVERY, 2019, 9 (09) :1208-1227
[5]   Immune checkpoint inhibition in early-stage triple-negative breast cancer [J].
Varma, Revati ;
Wright, Matthew ;
Abraham, Jame ;
Kruse, Megan .
EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (11) :1225-1238
[6]   Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model [J].
Maia, A. R. R. ;
de Man, J. ;
Boon, U. ;
Janssen, A. ;
Song, J. -Y. ;
Omerzu, M. ;
Sterrenburg, J. G. ;
Prinsen, M. B. W. ;
Willemsen-Seegers, N. ;
de Roos, J. A. D. M. ;
van Doornmalen, A. M. ;
Uitdehaag, J. C. M. ;
Kops, G. J. P. L. ;
Jonkers, J. ;
Buijsman, R. C. ;
Zaman, G. J. R. ;
Medema, R. H. .
ANNALS OF ONCOLOGY, 2015, 26 (10) :2180-2192
[7]   The role of UBR2 in triple-negative breast cancer and its implications for immune checkpoint blockade therapy [J].
Jiang, Yanlin ;
Fu, Yi ;
Song, Xinyan ;
Xie, Yongjie ;
Shang, Xiaobin ;
Liang, Xi .
DISCOVER ONCOLOGY, 2025, 16 (01)
[8]   Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer [J].
Quintana, A. ;
Saini, K. S. ;
Vidal, L. ;
Peg, V. ;
Slebe, F. ;
Loibl, S. ;
Curigliano, G. ;
Schmid, P. ;
Cortes, J. .
ESMO OPEN, 2024, 9 (10)
[9]   The role of immune checkpoint inhibition in triple negative breast cancer [J].
Tarekegn, Kidist ;
Keskinkilic, Merve ;
Kristoff, Tyler J. ;
Evans, Sean T. ;
Kalinsky, Kevin .
EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) :1095-1106
[10]   Lidocaine enhances the efficacy of palbociclib in triple-negative breast cancer [J].
Han, Beom Seok ;
Jung, Kyung Hee ;
Lee, Ji Eun ;
Yoon, Young-Chan ;
Ko, Soyeon ;
Park, Min Seok ;
Lee, Yun Ji ;
Kim, Sang Eun ;
Cho, Ye Jin ;
Lee, Pureunchowon ;
Lim, Joo Han ;
Jang, Eunsoo ;
Kim, Hyunzu ;
Hong, Soon-Sun .
AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (07) :3083-3098